This is an editorial summary of research originally reported by The Lancet. ProductSafer does not claim ownership of the underlying research. All intellectual property belongs to the original publishers.
Free weekly digest
We track health and safety research on food, cosmetics, and household products and send you what matters. Join 27 readers.
What would you like to do next?
I use this product
Get the next safety alert before it goes viral
Free weekly digest of health findings about everyday products. No spam, unsubscribe any time.
Advertisement
Get the latest health findings delivered to your inbox. Only the important stuff. No spam.
We'll send a confirmation email. Unsubscribe anytime.
Oral semaglutide did not slow the progression of early-stage Alzheimer's disease in clinical trials. The drug was well-tolerated, but failed to show benefits for this condition. This finding matters because semaglutide is widely used for weight loss and diabetes, and researchers had hoped it might help prevent cognitive decline.
Oral semaglutide was not efficacious in slowing clinical progression in participants with early Alzheimer's disease. Safety and tolerability of semaglutide in early Alzheimer's disease is consistent with studies in other indications.
This summary is based on reporting by The Lancet. For the complete article and full research details, see the original report linked below.
Always consult a healthcare professional for personal medical advice.
Read the full report at the original source
The LancetWas this finding useful?
Community discussion
Join the discussion
Comments are reviewed before appearing publicly.